How to buy ObsEva stock (OBSV)

ObsEva is a biotechnology & medical research business based in the US. ObsEva shares (OBSV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.08 – the same closing value as a week prior. ObsEva employs 48 staff and has a trailing 12-month revenue of around $3.7 million.

Our top picks for where to buy ObsEva stock

Buy ObsEva stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ObsEva stock price (NASDAQ: OBSV)

Use our graph to track the performance of OBSV stocks over time.

ObsEva shares at a glance

• Key figures

Information last updated 2024-06-30.

Latest market close	$0.08
52-week range	$0.00 - $0.00
50-day moving average more info button	$0.14
200-day moving average more info button	$0.27
Wall St. target price	$12.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.74

Is it a good time to buy ObsEva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ObsEva price performance over time

Historical closes compared with the close of $0.084 from 2023-04-24

1 week (2024-10-19)	N/A
1 month (2024-09-26)	N/A
3 months (2024-07-26)	N/A
6 months (2024-04-26)	N/A

1 year (2023-10-26)	N/A
2 years (2022-10-28)	-55.27%
3 years (2021-10-29)	2.6
5 years (2019-10-30)	7.66

ObsEva financials

Revenue TTM	$3.7 million
Gross profit TTM	$17,000
Return on assets TTM	-50.26%
Return on equity TTM	-373.98%
Profit margin	0%
Book value	$-0.03
Market Capitalization more info button	$11 million

TTM: trailing 12 months

ObsEva share dividends

We're not expecting ObsEva to pay a dividend over the next 12 months.

Have ObsEva's shares ever split?

ObsEva's shares were split on a 13:1 basis on 5 December 2016 . So if you had owned 1 share the day before before the split, the next day you'd have owned 13 shares. This wouldn't directly have changed the overall worth of your ObsEva shares – just the quantity. However, indirectly, the new 92.3% lower share price could have impacted the market appetite for ObsEva shares which in turn could have impacted ObsEva's share price.

ObsEva share price volatility

Over the last 12 months, ObsEva's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ObsEva's is 0.6745. This would suggest that ObsEva's shares are less volatile than average (for this exchange).

ObsEva overview

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland. .

Frequently asked questions

What percentage of ObsEva is owned by insiders or institutions?
Currently 2.016% of ObsEva shares are held by insiders and 13.423% by institutions. How many people work for ObsEva?
Latest data suggests 48 work at ObsEva. When does the fiscal year end for ObsEva?
ObsEva's fiscal year ends in December. Where is ObsEva based?
ObsEva's address is: Chemin des Aulx, 12, Geneva, Switzerland, 1228 What is ObsEva's ISIN number?
ObsEva's international securities identification number is: CH0346177709 What is ObsEva's CUSIP number?
ObsEva's Committee on Uniform Securities Identification Procedures number is: H5861P103